Electronic Arts (NASDAQ:EA) stock is seeing red on Wednesday following rumors that the video game company may not renew a deal for the FIFA name. Source: ricochet64./Shutterstock.com According to these rumors, EA and FIFA aren’t seeing eye-to-eye in negotiations over using the latter’s name. As a result, EA may be preparing to move ahead with…

DatChat (NASDAQ:DATS) stock is on the move Wednesday despite a lack of news from the social media messaging service. Source: Sfio Cracho / Shutterstock.com So what exactly is happening with DATS stock today? It looks like shares are caught up in a pump and dump as retail traders chatter about it online. We’ve seen a…

Crispr Therapeutics (NASDAQ:CRSP) stock is falling on Wednesday following the release of new results from a Phase 1 clinical trial. Source: Shutterstock These results were mostly positive with the company reporting 58% overall response rate and 38% complete response rate in large B-cell lymphoma. The drug was also well-tolerated with only two patients suffering Grade…

The stock market can be quite a difficult place to navigate these days. Indeed, U.S. stocks are not at all cheap at the moment. The ratio of stock market capitalization to GDP (Gross Domestic Product) shows that stocks in the U.S. are the most overvalued in history. That includes the dot-com bubble, by the way.…

In the 1980s, the field of genetics surged in popularity. At the time, I’m sure there were many articles promising investors that genetics stocks were on the cusp of spectacular gains. Investors who were looking for short-term payoffs then were disappointed, but now, gene editing stocks look far more promising. Researching the genetic origin behind…

Healthcare stocks are once again in the spotlight as the delta variant rides a new wave of coronavirus infections across the globe. As countries batten down the hatches again, it’s not surprising to see investors once again turn their attention towards the healthcare industry. With that in mind, let’s take a look at the healthcare…

Investing in the biotechnology sector doesn’t have to be fraught with excessive risk. A case in point would be CRISPR Therapeutics (NASDAQ:CRSP), as CRSP stock offers outstanding value in a market that’s often overpriced. CRISPR’s mission is “Creating transformative gene-based medicines for serious diseases.” The company’s pipeline of therapeutic candidates address serious conditions such as sickle-cell…

Today, gene editing stocks are once again in focus for investors. Indeed, today’s moves in a number of the most prominent stocks in this space are worth noting. Editas Medicine (NASDAQ:EDIT), Intellia Therapeutics (NASDAQ:NTLA) and CRISPR (NASDAQ:CRSP) are all up between 6% and 17% today. Source: Shutterstock These outsized moves come on a very green day in financial…

Shares of CRISPR Therapeutics (NASDAQ:CRSP) stock are ticking higher on Friday after the company reported a positive business update and financial results for the second quarter of fiscal year 2021 on Thursday. Source: Catalin Rusnac/ShutterStock.com There was plenty to be excited about in the release from the biopharmaceutical firm. However, what’s catching investors’ attention is…

For investors interested in gene editing, Crispr Therapeutics (NASDAQ:CRSP) stock is a must-watch. The company’s gene-editing platform promises to deliver therapies across sickle cell disorders, cancer and diabetes, among other diseases.  Source: Shutterstock Yet while CRSP stock does possess massive potential, there are lots of reasons to believe it may never achieve its lofty goals.…

Crispr Therapeutics AG (NASDAQ:CRSP) has the kind of DNA to become the next big thing in the market. But how does CRSP stock shape up as a purchase for today’s investors? Let’s take a look at what’s happening off and on the price chart, then offer a risk-adjusted determination aligned with those findings. Source: Catalin…

Biotechnology has always been one of the most relevant sectors. But with the onslaught of the novel coronavirus pandemic, more people have tuned into this vital segment of the economy. Hopefully, as Covid-19 fades permanently away, we may end up turning to companies like CRISPR Therapeutics (NASDAQ:CRSP) for resolving chronic issues instead of addressing acute…

Gene editing could revolutionize the way we treat diseases. By removing cells from the body, modifying them and reintroducing them, therapies could treat cancers, cystic fibrosis, sickle cell and muscular dystrophy. At some point, perhaps, this could extend to treating all known disease. “While the technology is still fairly new, academic institutes and biopharma companies…